Royalty Pharma Posts 16% Receipt Growth, Hits $12 Billion Deployment Target Early
Royalty Pharma’s portfolio receipts grew 16% in 2025, with Q4 receipts up 18%, and the company delivered a 15.8% return on invested capital while meeting its $10–12 billion deployment target a year ahead of plan. It completed $4.7 billion in transactions, secured FDA approval for Myqorzo and projects 2026 receipts of $3.275–3.425 billion despite upcoming Promacta exclusivity loss and a Tysabri biosimilar launch.
1. 2025 Financial Performance
In 2025, Royalty Pharma recorded a 16% increase in total portfolio receipts and an 18% rise in Q4 alone, delivered a 15.8% return on invested capital and met its $10–12 billion five-year deployment target a full year early.
2. Strategic Transactions and Clinical Milestones
The company completed $4.7 billion in royalty acquisitions focused on high-value therapies and benefited from FDA approval of Myqorzo, while management highlighted growing demand for synthetic royalties as an alternative financing model for biotech firms.
3. 2026 Outlook and Headwinds
Royalty Pharma forecasts 2026 portfolio receipts between $3.275 and $3.425 billion, implying 3%–8% growth, but expects pressure from the upcoming loss of Promacta exclusivity and the U.S. launch of a Tysabri biosimilar.
4. Portfolio Composition
The firm holds royalty interests on over 35 commercial products, including Imbruvica, Tysabri and Vertex’s cystic fibrosis franchise, in addition to ten development-stage candidates set to drive future receipts.